Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-A2-A4S1-01A-21R-A266-07

— · A

28111ef1-92e2-5305-ad0c-59426f5f84c5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
27
os_event
false

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.570
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
  • MYOGENESIS+0.420
  • ALLOGRAFT_REJECTION+0.380
  • INFLAMMATORY_RESPONSE+0.380
  • NOTCH_SIGNALING+0.360
  • IL6_JAK_STAT3_SIGNALING+0.350
  • COAGULATION+0.340
  • INTERFERON_GAMMA_RESPONSE+0.340
  • COMPLEMENT+0.330

Top 10 suppressed

  • MYC_TARGETS_V2-0.510
  • E2F_TARGETS-0.500
  • MYC_TARGETS_V1-0.500
  • G2M_CHECKPOINT-0.470
  • ESTROGEN_RESPONSE_EARLY-0.440
  • PROTEIN_SECRETION-0.340
  • ESTROGEN_RESPONSE_LATE-0.330
  • MITOTIC_SPINDLE-0.290
  • OXIDATIVE_PHOSPHORYLATION-0.210
  • BILE_ACID_METABOLISM-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120120155.TNBC
breast-umap@18
—D0.910
2TCGA-AC-A3W5-01A-11R-A22K-07
breast-umap@18
—D0.910
3TCGA-BH-A6R9-01A-21R-A32P-07
breast-umap@18
—A0.897
4BSR_12_0273_A5_S86
breast-umap@18
—A0.892
5TCGA-AC-A3W6-01A-12R-A22K-07
breast-umap@18
—A0.885
6TCGA-A2-A0EP-01A-52R-A22U-07
breast-umap@18
—A0.884
7SRR25617929
breast-umap@18
—A0.883
8SRR25043631
head-neck@1
——0.881
9TCGA-BH-A0DI-01A-21R-A12P-07
breast-umap@18
—A0.880
10TCGA-AN-A0FN-01A-11R-A034-07
breast-umap@18
—A0.879

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.570Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.550Inavolisib— uncovered
MYOGENESIS0.420Inavolisib— uncovered
ALLOGRAFT_REJECTION0.380Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.380Idelalisib— uncovered
NOTCH_SIGNALING0.360Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.350Inavolisib— uncovered
COAGULATION0.340Binimetinib— uncovered
INTERFERON_GAMMA_RESPONSE0.340Idelalisib— uncovered
COMPLEMENT0.330Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.330Inavolisib— uncovered
KRAS_SIGNALING_UP0.330Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.310Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
APICAL_JUNCTION0.270Inavolisib— uncovered
HEDGEHOG_SIGNALING0.250Inavolisib— uncovered
KRAS_SIGNALING_DN0.180Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.170Inavolisib— uncovered
IL2_STAT5_SIGNALING0.160Idelalisib— uncovered